Phase 1 Parkinson's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For all participants (both parts of the trial):

• People whose body mass index (a measure of body weight relative to height) falls between 18 and 34 kg/m²
• People whose veins are suitable for blood draws or receiving the study drug through a drip (IV), or both

For Part A only (single dose portion):

• People aged 30 to 85 years old at the time of signing the consent form
• People who are generally in good health
• For Chinese participants: people whose four biological grandparents are all of exclusively Chinese descent and were born in China
• For Japanese participants: people whose biological parents and all four biological grandparents are of exclusively Japanese descent and were born in Japan

For Part B only (multiple dose portion):

• People aged 40 to 85 years old at the time of signing the consent form
• People who have been diagnosed with Parkinson's disease according to specific UK medical diagnostic guidelines
• People with Parkinson's disease who are not currently on treatment, and whose condition is not expected to need new treatment started within the next 52 weeks
• People with Parkinson's disease who are currently on a stable dose of Parkinson's medication (such as levodopa/carbidopa, dopamine agonists, or MAO-B inhibitors) for at least 90 days before the study starts, with no expected changes for 52 weeks
• People who score 24 or above on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA)

Who may not be able to join:

For all participants (both parts of the trial):

• People with a significant neurological condition affecting the brain or nervous system (other than Parkinson's disease in Part B)
• People with serious or unstable health conditions that, in the doctor's view, could interfere with the study results, increase the risks of the study drug, or mean a life expectancy of less than 24 months
• People with known allergies to the study drug (LY4006896), related compounds, or any of its ingredients, or who have had allergic reactions to similar antibody-based medicines
• People with significant allergies to humanised monoclonal antibody medicines (a type of laboratory-made protein used as medicine)
• People with a history of severe or complex drug allergies, or serious skin reactions to medicines, or severe reactions after previous treatments (confirm with trial site for specific conditions listed)
• People with a history of uncontrolled asthma, significant autoimmune disease, a condition called hereditary angioedema, or a known immune deficiency condition
• People with clinically significant anaemia (low red blood cell levels)

For Part A only (single dose portion):

• People with abnormal blood pressure or heart rate as assessed by the investigating doctor, or a pre-existing history of high blood pressure

For Part B only (multiple dose portion):

• People with abnormal blood pressure or heart rate as assessed by the investigating doctor, or uncontrolled high blood pressure (systolic above 150 mmHg or diastolic above 95 mmHg at screening or treatment visits)
• People who have an implanted deep brain stimulation device or any other implanted nerve stimulation device (such as spinal cord or vagus nerve stimulators)
• People currently receiving Parkinson's medications through continuous infusion methods, such as under-the-skin pumps or intestinal delivery systems (confirm specific medications with trial site)

Important: Always verify eligibility with the trial site directly before applying.